Cytosorbents (NASDAQ:CTSO) Receives Buy Rating from B. Riley

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by B. Riley in a report issued on Wednesday, November 27th, Stock Target Advisor reports. They presently have a $12.00 target price on the medical research company’s stock. B. Riley’s price objective suggests a potential upside of 206.91% from the company’s previous close.

Several other brokerages also recently weighed in on CTSO. ValuEngine downgraded Cytosorbents from a “buy” rating to a “hold” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Cytosorbents in a research report on Tuesday, November 26th. Finally, Maxim Group restated a “buy” rating and set a $8.00 price target on shares of Cytosorbents in a research note on Monday, November 25th.

Shares of NASDAQ:CTSO traded down $0.09 during trading hours on Wednesday, hitting $3.91. The company’s stock had a trading volume of 174,823 shares, compared to its average volume of 214,328. The company has a debt-to-equity ratio of 1.88, a current ratio of 2.40 and a quick ratio of 2.21. The company has a market capitalization of $129.70 million, a price-to-earnings ratio of -6.98 and a beta of 1.64. Cytosorbents has a 52 week low of $3.49 and a 52 week high of $8.82. The firm’s fifty day moving average price is $4.25 and its 200 day moving average price is $5.34.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 165.00%. The company had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $6.49 million. On average, equities research analysts predict that Cytosorbents will post -0.62 earnings per share for the current fiscal year.

In other Cytosorbents news, CEO Phillip P. Chan purchased 16,500 shares of Cytosorbents stock in a transaction on Friday, December 6th. The stock was bought at an average cost of $3.96 per share, with a total value of $65,340.00. In the last quarter, insiders purchased 20,500 shares of company stock worth $80,650. 5.60% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Skylands Capital LLC lifted its position in Cytosorbents by 7.0% during the second quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock valued at $4,499,000 after purchasing an additional 44,550 shares during the period. Advisor Group Inc. raised its stake in shares of Cytosorbents by 15.8% during the 2nd quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock valued at $219,000 after buying an additional 4,530 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Cytosorbents by 31.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 81,270 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 19,439 shares during the period. Avenir Corp lifted its holdings in Cytosorbents by 66.6% in the second quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock valued at $960,000 after acquiring an additional 58,060 shares during the period. Finally, Sargent Investment Group LLC boosted its position in Cytosorbents by 15.9% in the 2nd quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock worth $2,207,000 after purchasing an additional 45,840 shares in the last quarter. Hedge funds and other institutional investors own 26.06% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Article: What is the Beige Book?

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.